NCT06155500View on ClinicalTrials.gov

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

January 11, 2039

Study Completion Date

January 11, 2039

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

OTQ923

There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Ctr, New York

38105

St Jude Childrens Research Hospital, Memphis

60637

University of Chicago, Chicago

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY